

Efficacy of Herbal Medicine as an Adjunctive Therapy of Chemotherapy for Cervical Cancer: A Systematic Review and Meta-analysis

Seung Yun Oh[#], Mi Suk Kim^{1#}, Jong Cheon Joo^{*}, Yung Sun Song^{1*}

Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University,

1 : Department of Third Medicine of Korean Medicine, Professional Graduate School of Korean Medicine, Wonkwang University

This study aimed to evaluate the efficacy of herbal medicine (HM) combined with chemotherapy (CT) for cervical cancer. Ten electronic databases including Pubmed, Cochrane library, Embase, Korean databases, and Chinese medical databases were systematically searched up to October 2019. All randomized controlled trials with HM combined with CT to treat cervical cancer were included. A total of 21 trials were included for analysis. Compared to the control group, HM combined with CT group significantly increased tumor response (complete and partial response) (risk ratio [RR] = 1.24, 95% CI: 1.15-1.33, $p < 0.00001$) and Karnofsky performance score (standardized mean difference [SMD] = 1.71, 95% CI: 1.41-2.01, $p < 0.00001$). Also, HM combined with CT group remarkably reduced CT toxicity. In Conclusion, our study suggests that HM might be a potential option for cervical cancer to enhance curative efficacy and reduce CT toxicity.

keywords : Chemotherapy, Herbal medicine, Cervical cancer, Systematic review, Meta-analysis

Introduction

Cervical cancer is the fourth most common malignant tumor among women worldwide, with almost 0.6 million cases and 0.3 million deaths per year, and is a major public health problem affecting middle-aged women¹. Despite of advances in early screening methods, the incidence of cervical cancer is still high, particularly in some low- and middle-income countries². Despite of considerable advances in treatments for cervical cancer, the clinical application is limited by surgery-related complications, disease recurrence, and therapy-related side effects. It is well known that Chemotherapy (CT) is usually accompanied by adverse events, including hematologic and gastrointestinal toxicity^{3,4}. Conventional symptomatic therapy to reduce adverse events is commonly used, but the effect is not significant.

Herbal medicine (HM) has been widely used in cancer treatment for a long time because of its efficacy and low

toxicity. In vitro and in vivo studies on cervical cancer indicated that crude extracts or bioactive compounds from HM inhibited proliferation and induced apoptosis⁵. A meta-analysis of RCTs also suggested that HM improved quality of life in cancer patients⁶. In addition, HM has a good effect on cancer symptoms and reducing side effects⁷. Numerous studies have reported the effectiveness of HM as an adjuvant therapy for cancer⁸, but there is no systematic review and meta-analysis on the efficacy of HM in patients with cervical cancer.

This study aimed to observe the effect of HM combined with CT on tumor response, quality of life, and reduction of CT toxicity in patients with cervical cancer.

Material and Methods

1. Data sources and search strategy

The search was conducted in the following ten electronic databases to October 2019: Pubmed, Cochrane

* Corresponding author

Jong Cheon Joo, Department of Sasang Constitutional Medicine, Wonkwang University Jeonju Korean Medicine Hospital, 99, Garyeonsan-ro, Deokjin-gu, Jeonju-si, Jeollabuk-do, Rep. of Korea

E-mail : jcjoo@wku.ac.kr Tel : +82-63-270-1073

Yung Sun Song, Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Wonkwang University, 460, Iksan-daero, Iksan-si, Jeollabuk-do, Rep. of Korea

E-mail : yssong@wku.ac.kr Tel : +82-63-850-5114

Received : 2020/09/24 Revised : 2020/10/13 Accepted : 2020/10/15

© The Society of Pathology in Korean Medicine, The Physiological Society of Korean Medicine

pISSN 1738-7698 eISSN 2288-2529 <http://dx.doi.org/10.15188/kjopp.2020.10.34.5.255>

Available online at <https://kmpath.jams.or.kr> & <http://jppkm.org>

Both authors contributed equally to this work

library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, Journal integration platform (VIP), Korean Medical Database (KMBASE), National Discovery for Science Leaders (NDSL), Oriental Medicine Advanced Searching Integrated System (OASIS), and Korean studies Information Service System (KISS). We also searched the references of all included studies by hand, the grey literature, dissertations, letters, government documents, research reports, conference proceedings and abstracts to avoid publication bias. 'Uterine cervical neoplasms' and 'Chinese herbal medicine' were the main keywords in our search strategy. The detailed search strategy is presented in supplementary 1.

2. Eligibility criteria

1) Types of studies

Only randomized controlled trials (RCTs) were eligible. Non-RCTs, quasi-RCTs, in vitro and animal studies were excluded.

2) Types of participants

Eligible studies included women with a clear diagnosis of cervical cancer confirmed by pathological sections. Also, all participants in the treatment and control groups were treated with CT. No restrictions were placed on age, ethnicity, degree of pain, surgery or disease duration.

3) Types of interventions

The patients in the treatment group were treated by HM combined with CT, while the control group was treated with only CT. Because there were the most studies using herbal medicine as adjuvant therapy for CT rather than monotherapy in a preliminary search. The included studies used HM in various forms such as decoctions, capsules, and tablets, except intravenous administration. Both monochemotherapy and polychemotherapy were included, and combination with radiotherapy was excluded.

4) Types of outcome measures

Tumor response and Karnofsky performance score (KPS) were the primary outcomes. CT toxicity was the secondary outcome.

3. Study selection and data extraction

Two reviewers (SYO and MSK) independently screened the articles according to the inclusion and exclusion criteria, and extracted the data based on standardized data collection form. When the two reviewers had disagreements during the process, they were resolved by consensus or inviting a third reviewer (JCJ). The following data were extracted: first author, year, sample size, patient characteristics, intervention details, outcomes.

4. Quality assessment

Two independent reviewers assessed methodological quality by using the Cochrane risk of bias tool (RoB) tool⁹. Disagreements between the two reviewers were resolved by discussion with a third reviewer (JCJ). The following items were used to assess the methodological quality of RCTs: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias.

5. Statistical analysis

The RevMan 5.3 software of the Cochrane Collaboration was used for data analysis. For dichotomous data, the risk ratio (RR) and 95% confidence interval (CI) were reported. For continuous variables, standardized mean difference (SMD) with 95% CI was reported. We used random effects model to estimate treatment effects. Heterogeneity was assessed using the I^2 statistic, and $I^2 > 50\%$ was assumed as high heterogeneity. P value < 0.05 was considered statistically significant.

Results

A total of 3937 studies were identified through searching PubMed (n=159), Cochrane library (n=187), Embase (n=2074), CNKI (n=378), Wanfang database (n= 967), VIP (n=5), KISS (n= 55), Kmbase (n= 27), NDSL (n= 82), and OASIS (n= 3). The screening process is shown in Fig. 1. A total of 471 articles were excluded in screening the duplicates. After reviewing the titles and abstracts, 3404 studies were excluded additionally because they did not meet the criteria. The full texts of 62 studies were reviewed, and 21 studies¹⁰⁻³⁰ were finally included for this systematic review and meta-analysis.

1. Study characteristics

The included studies were all conducted in China and published in Chinese between 2014 and 2019. A total of 21 studies with 1647 patients were analyzed: 824 patients were in HM combined with CT group, and the other 823 patients were in CT alone group. The characteristics of the studies including sample size, age, duration, outcomes etc. were shown in Table 1. HM used in the included studies were Fuzhengguben decoction, BaZhen decoction, Modified RenShenYangRong decoction, and so on (supplementary 2).

2. Risk of Bias in Included Studies

The risk of bias in included studies is shown in Fig. 2. All studies were described as randomized, and 11 studies^{10,14,18-22,25,26,29,30} used random number tables. None of the studies described the allocation concealment. All studies had high risk of bias in blinding of participants and

personnel, because they did not use placebo in control group. All studies were unclear on blinding of outcome assessment and selective reporting outcome. Other bias was also evaluated as unclear in all studies due to insufficient information.

Table 1. Characteristics of included studies

Author, Year	Sample size (TG/CG)	Age (years)	FIGO CC stage (NO. of patients)	Duration	Intervention of TG	Intervention of CG	Outcomes
Chang et al. 2018 ¹⁰	84 (42/42)	TG: 48.75 ± 10.24 CG: 48.25 ± 10.13	TG: III, 26; IV, 16 CG: III, 25; IV, 17	4 weeks*3 courses	HM + Paclitaxel/ Cisplatin	Paclitaxel/ Cisplatin	1. Tumor response
Gong et al. 2018 ¹¹	64 (32/32)	TG: 47.9 ± 2.4 CG: 48.2 ± 2.5	TG: I, 13; II, 12; III, 7 CG: I, 11; II, 13; III, 8	21 days*2 courses	HM + Paclitaxel/ Cisplatin	Paclitaxel/ Cisplatin	1. Tumor response
Han et al. 2016 ¹²	72 (36/36)	TG: 47.5 ± 12.4 CG: 49.1 ± 8.2	TG: I A 7; I B, 15; II A 10; II B, 4 CG: I A, 10; I B, 12; II A, 8; II B, 6	3 months	HM+ Cisplatin/ Irinotecan	Cisplatin/ Irinotecan	1. KPS
Jian et al. 2015 ¹³	41 (21/20)	TG: 52.38 ± 8.09 CG: 50.55 ± 9.81	TG: III A, 2; III B 3; IV A, 3; IV B, 13 CG: III A, 3; III B 4; IV A, 2; IV B, 11	CT: 21 days*2 courses HM: 8 weeks	HM+Cisplatin/ Docetaxel	Cisplatin/ Docetaxel	1. Tumor response 2. KPS 3. Chemotoxicity
Li et al. 2017 ¹⁴	60 (30/30)	TG: 33.3 ± 1.5 CG: 33.5 ± 1.7	TG: I, 17; II, 13 CG: I, 18; II, 12	CT: 5 days*2 courses HM: 10 days*2 courses	HM+ Cisplatin/ Fluouracil	Cisplatin/ Fluouracil	1. Chemotoxicity
Li et al. 2019 ¹⁵	61 (30/31)	TG: 47.53 ± 9.25 CG: 48.15 ± 9.34	TG: I B1, 10; I B2, 12; II A, 8 CG: I B1, 10; I B2, 12; II A, 9	21 days*5 courses	HM+ Cisplatin/ Docetaxel	Cisplatin/ Docetaxel	1. Tumor response 2. KPS 3. Chemotoxicity
Liu 2019 ¹⁶	100 (50/50)	TG: 54.11 ± 2.42 CG: 54.25 ± 2.47	TG: II B, 21; III, 19; IV, 10 CG: II B, 20; III, 20; IV, 10	8 weeks	HM+ Fluouracil/ Cyclophosphamide/ Pingyangmycin	Fluorouracil/ Cyclophosphamide/ Pingyangmycin	1. Tumor response
Nan et al. 2015 ¹⁷	60 (30/30)	TG: 48.8 ± 6.1 CG: 48.7 ± 6.3	TG: I, 5; II, 15; III, 10 CG: I, 6; II, 14; III, 10	4 weeks	HM+ Cisplatin + Irinotecan	Cisplatin+ Irinotecan	1. Chemotoxicity
Qin et al. 2016 ¹⁸	60 (30/30)	TG: 48.34 ± 5.35 CG: 50.45 ± 5.85	TG: II B, 18; III A, 5; III B, 7 CG: II B, 16; III A, 6; III B, 8	Not reported	HM+ Paclitaxel/ Irinotecan (Some patients combined Mitomycin/ Cisplatin/ 5-fluorouracil)	Paclitaxel/ Irinotecan (Some patients combined Mitomycin/ Cisplatin/ 5-fluorouracil)	1. Tumor response 2. KPS 3. Chemotoxicity
Sun et al. 2019 ¹⁹	116 (58/58)	TG: 55.46 ± 13.27 CG: 55.23 ± 13.12	TG: II B, 32; III A, 14; III B, 12 CG: II B, 33; III A, 12; III B, 13	CT: 21 days*1~2 courses HM:10 days*2 courses	HM+ Oxaliplatin/ Paclitaxel	Oxaliplatin/ Paclitaxel	1. Tumor response 2. KPS 3. Chemotoxicity
Wang 2014 ²⁰	90 (45/45)	TG: 53.2 ± 7.5 CG: 53.5 ± 7.8	TG: II B, 25; III A, 9; III B 11 CG: II B, 27; III A, 8; III B 10	Unclear	HM + Paclitaxel/ Irinotecan	Paclitaxel/ Irinotecan	1. Tumor response 2. KPS 3. Chemotoxicity
Wen et al. 2019 ²¹	114 (57/57)	TG: 56.37 ± 7.93 CG: 55.49 ± 7.62	TG: II A, 19; II B, 20; III A 18 CG: II A, 19; II B, 21; III A 17	7 days*3 courses	HM+ Paclitaxel/ Cisplatin	Paclitaxel/ Cisplatin	1. Tumor response 2. Chemotoxicity
Wu 2017 ²²	80 (40/40)	Total: 56.3 ± 7.2	II B 26, III A, 38, III B, 16	Unclear	HM+ Paclitaxel/ Irinotecan	Paclitaxel/ Irinotecan	1. Tumor response 2. Chemotoxicity
Xu et al. 2018 ²³	90 (45/45)	TG: 53.3 ± 7.6 CG: 53.1 ± 7.4	TG: II B, 23; III A, 10; III B, 12 CG: II B, 24; III A, 10; III B, 11	Unclear	HM+ Paclitaxel / Irinotecan	Paclitaxel / Irinotecan	1. Tumor response 2. Chemotoxicity
Xu et al. 2019 ²⁴	60 (30/30)	TG: 50.13 ± 14.26 CG: 50.27 ± 13.49	TG: I B1, 13; I B2, 10; II A, 5; II B, 2 CG: I B1, 14; I B2, 10; II A, 4; II B, 2	Unclear	HM+ Paclitaxel/ Irinotecan	Paclitaxel/ Irinotecan	1. Tumor response
Yang 2015 ²⁵	80 (40/40)	TG: 58.7 ± 7.9 CG:59.4 ± 6.1	TG: I B, 7; II A, 5; II B, 19; III A, 5; III B, 4 CG: I B, 6; II A, 4; II B, 20; III A, 6; III B, 4	CT: 3 weeks* 3 courses HM: 9 weeks	HM+ Cisplatin/ Mitomycin/5-fluorouracil	Cisplatin/ Mitomycin /5-fluorouracil	1. Tumor response 2. Chemotoxicity
Yang 2017 ²⁶	119 (60/59)	TG: 55.37 ± 12.82 CG: 54.86 ± 12.97	TG: II A, 18; II B, 30; III 12 CG: II A, 17; II B, 28; III 14	3 months	HM+ Oxaliplatin/ Paclitaxel	Oxaliplatin/ Paclitaxel	1. Tumor response
Yang et al. 2018 ²⁷	62 (31/31)	TG: 48.24 ± 1.13 CG: 48.64 ± 1.33	TG: II B, 12; III A, 5; III B, 14 CG: II B, 10; III A, 3; III B, 18	CT: 5 days HM: 10 days	HM + Paclitaxel/ Cisplatin	Paclitaxel/ Cisplatin	1. Tumor response 2. Chemotoxicity
Zhang et al. 2015 ²⁸	56 (28/28)	TG: 52.6 CG: 56.3	TG: III A, 12; III B, 8; IV, 8 CG: III A, 10; III B, 16; IV, 2	21 days*3 courses	HM+ Paclitaxel/ Cisplatin	Paclitaxel/ Cisplatin	1. Tumor response 2. Chemotoxicity
Zhu et al. 2019 ²⁹	92 (46/46)	TG: 54.03 ± 7.12 CG: 53.29 ± 6.37	TG: II B, 31; III, 15 CG: II B, 32; III, 14	4 weeks*3 courses	HM+ Cisplatin/ Docetaxel	Cisplatin/ Docetaxel	1. Tumor response 2. Chemotoxicity
Zuo 2019 ³⁰	86 (43/43)	TG: 46.53 ± 3.27 CG: 46.62 ± 3.87	TG: II B, 18; III A, 13; III B, 12 CG: II B, 17; III A, 15; III B, 11	21 days*2 courses	HM+ Paclitaxel/ Irinotecan	Paclitaxel/ Irinotecan	1. Tumor response 2. Chemotoxicity

CC, cervical cancer; TG, treatment group; CG, control group; HM, herbal medicine; CT, chemotherapy; AEs, adverse events; KPS, Karnofsky performance scale; NK, natural killer; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; Cr, creatinine; SCC-Ag, squamous cell carcinoma antigen; TSGF, tumor supplied group of factors; EORTC QLQ-C30, the European organisation for research and treatment of cancer quality of life questionnaire; VAS, visual analogue scale; SF-36, short form-36




Fig. 1. Study flow diagram.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chang et al. 2018	?	?	?	?	?	?	?
Gong et al. 2018	?	?	?	?	?	?	?
Han et al. 2016	?	?	?	?	?	?	?
Jian et al. 2015	?	?	?	?	?	?	?
Li et al. 2017	?	?	?	?	?	?	?
Li et al. 2019	?	?	?	?	?	?	?
Liu 2019	?	?	?	?	?	?	?
Nan et al. 2015	?	?	?	?	?	?	?
Qin et al. 2016	?	?	?	?	?	?	?
Sun et al. 2019	?	?	?	?	?	?	?
Wang 2014	?	?	?	?	?	?	?
Wen et al. 2019	?	?	?	?	?	?	?
Wu 2017	?	?	?	?	?	?	?
Xu et al. 2018	?	?	?	?	?	?	?
Xu et al. 2019	?	?	?	?	?	?	?
Yang 2015	?	?	?	?	?	?	?
Yang 2017	?	?	?	?	?	?	?
Yang et al. 2018	?	?	?	?	?	?	?
Zhang et al. 2015	?	?	?	?	?	?	?
Zhu et al. 2019	?	?	?	?	?	?	?
Zuo 2019	?	?	?	?	?	?	?

Fig. 2. Risk of bias summary.

3. Meta-analysis

1) Tumor response

18 studies^{10,11,13,15,16,18-30} reported complete response (CR) or partial response (PR). As shown in Fig. 3, HM therapy combined with CT was associated with a significant increase in the number of patients who reported complete or partial response (RR = 1.24, 95% CI: 1.15-1.33, p < 0.00001, I² = 5%).





Fig. 3. The forest plot of tumor response of HM combined with CT versus CT alone. HM, herbal medicine; CT, chemotherapy; CR, complete response; PR, partial response.

2) Karnofsky performance score

KPS scores were reported as two types, the mean ± SD of KPS before and after treatment, and the number of patients who reported the improved or stable performance status based on KPS (ten-point cutoff). The value of KPS was recorded in three studies^{15,18,19} with 237 patients. Meta-analysis reported that KPS score was significantly increased in HM combined with CT group compared with CT alone group (SMD = 1.71, 95% CI: 1.41-2.01, p < 0.00001, I² = 0%, Fig. 4A). The non-deterioration KPS was recorded in two studies^{13,20} with 131 patients. The results of meta-analysis found that there was no significant difference between the two groups (RR = 1.12, 95% CI: 0.92-1.38, p = 0.32, I² = 0%, Fig. 4B).

A



B




Fig. 4. The forest plot of KPS of HM combined with CT versus CT alone; outcomes: (A) mean ± SD of KPS; (B) number of patients with non-deterioration KPS. KPS, Karnofsky performance score; HM, herbal medicine; CT, chemotherapy.




Fig. 5. The forest plot of CT toxicity (including nausea and vomiting, hair loss, neurotoxicity, hepatic and renal toxicity) of HM combined with CT versus CT alone. HM, herbal medicine; CT, chemotherapy.

3) CT Toxicity

Nausea and vomiting were recorded in eight studies^{13,20-23,25,29,30}. Meta-analysis showed that the incidence of nausea and vomiting was significantly lower in HM combined with CT group than in CT alone group (RR = 0.58, 95% CI: 0.50-0.68, $p < 0.00001$, $I^2 = 0\%$, Fig. 5 (1.2.1)). Hair loss was reported in eight studies^{11,18,20-23,25,27}. Meta-analysis indicated that the incidence of hair loss was significantly lower in HM combined with CT group than in CT alone group (RR = 0.53, 95% CI: 0.42-0.66, $p < 0.00001$, $I^2 = 17\%$, Fig. 5 (1.2.2)). Neurotoxicity was recorded in eight studies^{12,18,20,22,23,25,27,28}. Meta-analysis found that the incidence of neurotoxicity was significantly lower in HM combined with CT group than in CT alone group (RR = 0.66, 95% CI: 0.49-0.88, $p = 0.005$, $I^2 = 0\%$, Fig. 5 (1.2.3)). Hepatic and renal toxicity were recorded in eight studies^{13,15,18,20,22,23,25,27,29,30}. The results of meta-analysis

reported that the incidence of hepatic and renal toxicity were significantly lower in HM combined with CT group than in CT alone group (RR = 0.51, 95% CI: 0.34-0.75, $p = 0.0007$, $I^2 = 0\%$, Fig. 5 (1.2.4)). Overall, the result showed that the incidence of CT toxicity was significantly lower in HM combined with CT group than in CT alone group (RR = 0.57, 95% CI: 0.51-0.63, $p < 0.00001$; $I^2 = 0\%$, Fig. 5).

Discussion

HM is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effect and decrease side effects combined with CT. To our knowledge, this is the first systematic review and meta-analysis of RCTs on the efficacy of HM in cervical cancer. This meta-analysis evaluated the outcomes including tumor response, quality of life (KPS), and CT toxicity. A total of 21 studies were included in this review, involving 1647 patients (824 in HM combined with CT group, and 823 in CT alone group).

The results of meta-analysis found that the tumor response was significantly in favor of HM combined with CT. Astragalus membranaceus, Angelica sinensis, Paeonia lactiflora, Atractylodes macrocephala were the most frequently used herbs in the included studies. According to the reports, these herbs had immunomodulatory function and anti-tumor effects through some mechanisms³¹⁻³³. The aqueous extract of Astragalus membranaceus could induce apoptosis of H22 tumor cells and had an inhibiting effect on tumor growth³⁴. Polysaccharide from Astragalus membranaceus had potent immunomodulatory activity by stimulating macrophages and increase the level of cytokines including tumor necrosis factor- α (TNF- α) and granulocyte-macrophage colony-stimulating factor (GM-CSF)³⁵. In addition, Wu et al. found that the combined therapy of Astragalus membranaceus and Angelica sinensis could attenuate cancer-related inflammation and had an inhibiting effect on tumor growth³⁶.

Both CT and radiotherapy have many side effects; therefore, it is necessary to find complementary and alternative approaches for reducing the side effects. In this meta-analysis, HM combined with CT significantly reduced side effects caused by CT, including nausea, vomiting, hair loss, neurotoxicity, hepatic and renal toxicity. HM usually comprises multiple herbs from natural origin. Acting of phytochemicals and herbal mixtures are multi-specific, so they attack multiple targets at the same time³⁷. Multi-target therapies have been advocated to overcome resistance to

anti-cancer drugs. Especially, polypharmacology has more advantages than drug combination in reducing side effects and selectivity for cancer cells³⁸). We hypothesize that these features of HM make it a good candidate for cervical cancer treatment.

The present study has some limitations. Firstly, although we conducted a comprehensive search, the included RCTs were only carried out in China. For this reason, the results might not be acceptable to other populations in other parts of the world. Secondly, the methodological qualities of included RCTs were generally poor. 11 RCTs reported having used "random number tables", while the other 10 RCTs only mentioned "randomization" and did not describe further details. The allocation concealment and blinding were not reported in all of included RCTs. In addition, most of them did not reported follow-up and drop-out rates; these methodological flaws might lead to potential biases, so the results should be interpreted with great caution. Thirdly, no placebo was used in all included RCTs. The characteristics of HM, like strong tastes and smells, can cause difficulty in making placebo, especially in decoctions. Also, we considered that it was due to clinical trial ethics on the treatment for cancer patients. This problem was considered as a high risk of bias in the blinding of participants and personnel. Fourthly, the long-term efficacy was not evaluated, because most of the studies did not give the data of long-term follow up. Lastly, none of the included studies reported responsible ethical committees have approved the experiments. Considering the importance of protecting the rights of patients, complementary and alternative medicine researchers must develop awareness of ethical issues.

Conclusion

In conclusion, our systematic review and meta-analysis results provide evidence for the efficacy of HM in cervical cancer treatment. HM might be an effective option to enhance curative efficacy and reduce chemotherapy toxicity. However, because the most of included studies had low quality, the results should be interpreted cautiously. To suggest stronger evidence for using HM in cervical cancer, high quality rigorous RCTs will be needed in the future.

Acknowledgement

This paper was supported by Wonkwang University in

2019.

References

1. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health*. 2020;8(2):e191-e203.
2. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. *Cancer Epidemiol Biomarkers Prev*. 2016;25(1):16.
3. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. *Lancet*. 2019;393(10167):169-82.
4. Vale C, Thierny JF, Stewart LA. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol*. 2008;26(35):5802-12.
5. Hsiao YH, Lin CW, Wang PH, Hsin MC, Yang SF. The Potential of Chinese Herbal Medicines in the Treatment of Cervical Cancer. *Integr Cancer Ther*. 2019;18:1534735419861693.
6. Chung VC, Wu X, Hui EP, Ziea ET, Ng BF, Ho RS, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. *Sci Rep*. 2015;5:18111.
7. Wang R, Sun Q, Wang F, Liu Y, Li X, Chen T, et al. Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis. *Front Oncol*. 2019;9:730.
8. Yan XY, Yan ZS, Liu WC, Ding H, Qiao SZ, Chen G, et al. External application of traditional Chinese medicine in the treatment of bone cancer pain: a meta-analysis. *Support Care Cancer*. 2016;24(1):11-7.
9. Higgins JPT, Altman DG. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions*, version 5.0.1. West Sussex, England: John Wiley & Sons Ltd. 2008:214-72.
10. Chang ZL, Sheng XB, Shi XL, Wei W. Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy. *J Capit Univ Med Sci*. 2018;39(4):596-601.
11. Gong SX, You JL, Ren CX. Clinical effect of Fuzheng Yin 1 combined with TP chemotherapy in the treatment of cervical cancer. *Acta Chin Med Pharm*. 2018;46(01):98-100.

12. Han L, Long LX, Tuo XY. Treating 36 cases of cervical carcinoma after laparoscopic operation by integrative medicine therapy. *West J Tradit Chin Med.* 2016;29(6):98-9.
13. Jian XL, Jiang YL, Zeng PH. Clinical efficacy of modified Fuzheng Xiaozheng formula combined with chemotherapy in treatment of advanced cervical cancer: a report of 21 cases. *Hunan J Tradit Chin Med.* 2015;31(06):1-3.
14. Li LD, Xu WF. Effect of Fuzheng Guben decoction combined with chemotherapy on immune function in cervical cancer patients. *Beijing J Tradit Chin Med.* 2017;36(04):362-4.
15. Li CX, Li SH. Effect of cisplatin and docetaxel chemotherapy combined with Zhenqi Fuzheng Granule on cervical cancer. *Drug Eval Res.* 2019;42(3):501-4.
16. Liu JZ. Analysis on the effectiveness of integrative medicine treatment for advanced cervical cancer. *Electron J Clin Med Lit.* 2019;6(61):18-9.
17. Nan F, Chen CH. Study on the clinical efficacy on 30 cases of cervical cancer treated with integrated Chinese and Western medicine. *World J Integr Tradit West Med.* 2015(11):1586-8.
18. Qin YY, Wei ZY, Han FX. Clinical efficacy and safety analysis of Fuzheng Guben decoction combined with chemotherapy for cervical cancer. *J Guangzhou Univ Tradit Chin Med.* 2016;33(03):321-4.
19. Sun M, Zhao Y, Yang TR, Tang XT, Ren Y. Effect of Fuzheng Guben decoction on the levels of SCC-Ag and TSGF in patients with cervical cancer. *Anti-tumor pharm.* 2019;9(01):120-4, 138.
20. Wang AL. Clinical efficacy and safety analysis of fuzhengguben soup combined with chemotherapy on cervical cancer. *China J Mod Med.* 2014;24(22):51-3.
21. Wen LF, Ding J. Effect of modified Renshen Yangrong tang combined with chemotherapy on serum tumor markers and Th1/Th2-type cytokines expression in cervical cancer patients. *Chin J Exp Tradit Med Formulae.* 2019;25(05):68-72.
22. Wu Y. Effect of Fuzheng Guben decoction combined with chemotherapy for cervical cancer. *China Prac Med.* 2017;12(24):107-8.
23. Xu LZ, Qi CJ. Clinical efficacy of Fuzheng Guben decoction combined with chemotherapy for cervical cancer. *Diet Health.* 2018;5(9):92.
24. Xu SL, Ming Y, Li K. Effectiveness of Fuzheng Guben decoction combined with chemotherapy for cervical cancer. *Home Med.* 2019(8):134.
25. Yang M. Clinical effect of Fuzheng Guben decoction combined with chemotherapy for cervical cancer. *J Pract Tradit Chin Med.* 2015;31(11):1036-7.
26. Yang HL. Effect of Jiawei Renshenyangrong decoction on immune function and quality of life of cervical cancer patients. *Acta Chin Med.* 2017;32(08):1377-80.
27. Yang XY, Wang LH. Clinical analysis of Sanxian Baogong decoction combined with cisplatin and paclitaxel in treatment of advanced cervical cancer. *Chin Arch Tradit Chin Med.* 2018;36(08):1936-9.
28. Zhang ZW, Ni ML. Effect of Sanxian Baogong decoction combined with paclitaxel and cisplatin in treatment of middle and advanced cervical cancer. *J Pract Gynecol Endocrinol.* 2015(3):73-5.
29. Zhu P, Li J. Effects of Fuzheng Yiliu decoction combined with chemotherapy on the levels of T cell subsets, serum tumor markers expression and survival rate in patients with middle and advanced cervical cancer. *Forum Tradit Chin Med.* 2019;34(01):18-20.
30. Zuo MF. Clinical efficacy of self-made Qinggan Lishi decoction in the treatment of patients with cervical cancer chemotherapy. *Hebei Med.* 2019;25(07):1226-31.
31. Feng Z, Yang R, Wu L, Tang S, Wei B, Guo L, et al. *Atractylodes macrocephala* polysaccharides regulate the innate immunity of colorectal cancer cells by modulating the TLR4 signaling pathway. *Onco Targets Ther.* 2019;12:7111-21.
32. Li Y, Gong L, Qi R, Sun Q, Xia X, He H, et al. *Paeoniflorin* suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. *Drug Des Devel Ther.* 2017;11:2481-91.
33. Liao KF, Chiu TL, Huang SY, Hsieh TF, Chang SF, Ruan JW, et al. Anti-Cancer Effects of *Radix Angelica Sinensis* (Danggui) and *N-Butylidenephthalide* on Gastric Cancer: Implications for REDD1 Activation and mTOR Inhibition. *Cell Physiol Biochem.* 2018;48(6):2231-46.
34. Li LK, Kuang WJ, Huang YF, Xie HH, Chen G, Zhou QC, et al. Anti-tumor effects of *Astragalus* on hepatocellular carcinoma in vivo. *Indian J Pharmacol.* 2012;44(1):78-81.
35. Zhao LH, Ma ZX, Zhu J, Yu XH, Weng DP. Characterization of polysaccharide from *Astragalus radix* as the macrophage stimulator. *Cell Immunol.* 2011;271(2):329-34.
36. Wu TH, Yeh KY, Wang CH, Wang H, Li TL, Chan YL, et al. The Combination of *Astragalus membranaceus* and *Angelica sinensis* Inhibits Lung Cancer and Cachexia through Its Immunomodulatory Function. *J Oncol.* 2019;2019:9206951.
37. Efferth T, Saeed MEM, Mirghani E, Alim A, Yassin Z,

- Saeed E, et al. Integration of phytochemicals and phytotherapy into cancer precision medicine. *Oncotarget*. 2017;8(30):50284-304.
38. Xie L, Bourne PE. Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. *Front Pharmacol*. 2015;6:209.